ADCs Reshape Frontline Metastatic Triple-Negative Breast Cancer
This narrative review consolidates the immunotherapy, antibody-drug conjugate, and PARP inhibitor evidence that pharmacists now need to sequence and support across biomarker-defined metastatic triple-negative breast cancer.
sacituzumab govitecandatopotamab deruxtecantrastuzumab deruxtecanpembrolizumabatezolizumabolaparibtalazoparibantibody-drug conjugatesimmune checkpoint inhibitorsPARP inhibitorstriple-negative breast cancermetastatic breast cancernarrative reviewtreatment sequencingbiomarkersOncology Pharmacy
Background Information
New therapies offer hope for aggressive TNBC.
Metastatic triple negative breast cancer (TNBC) has limited treatment options and high mortality, making new therapies critical. The review highlights advancements using immune checkpoint inhibitors, antibody-drug conjugates, PARP inhibitors, and targeted approaches. Offers a framework for biomarker-guided treatment selection in TNBC, emphasizing evolving therapies and resistance mechanisms. New therapies are transforming the management of metastatic TNBC, providing hope for improved outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.